Conquering the dark side: colloidal iron oxide nanoparticles.
Conquering the dark side: colloidal iron oxide nanoparticles.
复制标题
DOI：
10.1021/nn900819y
复制
发表时间：
2009-12-22
期刊：
影响因子：
17.1
通讯作者：
Lanzat, Gregory M.
中科院分区：
文献类型：
--
作者：
Senpan, Angana;Caruthers, Shelton D.;Rhee, Ilsu;Mauro, Nicholas A.;Pan, Dipanjan;Hu, Grace;Scott, Michael J.;Fuhrhop, Ralph W.;Gaffney, Patrick J.;Wickline, Samuel A.;Lanzat, Gregory M.
动脉粥样硬化疾病的纳米医学方法将对心血管医学的实践和结果产生重大影响。氧化铁纳米颗粒已被广泛用于非靶向和靶向成像应用的基础上，高度敏感的T2* 成像性能，这通常会导致负对比度的影响，只能成像后24小时或更长的全身性管理，由于持续血池干扰。虽然最近的进展，涉及MR脉冲序列已转换这些暗对比度体素到明亮的，显着的延迟，从持续的磁背景干扰和突出的偶极子晕效应的磁化率成像仍然是障碍，以克服。我们报告了一个T1加权（T1w）治疗诊断胶体氧化铁纳米颗粒平台，CION，这是通过在交联磷脂纳米乳液中包埋油酸酯涂层的磁铁矿颗粒实现的。与预期相反，该制剂降低了T2效应，从而允许在低纳摩尔浓度下进行阳性T1w对比检测。CION是一种体内给药的血管约束纳米平台，在治疗后1小时允许T1w分子成像，而没有血池干扰，尽管由超顺磁性颗粒诱导的对血液的一些T2缩短效应持续存在。此外，CION被证明封装抗血管生成药物，如烟曲霉素，并保留它们在延长溶解，这表明显着的治疗诊断功能。总的来说，CION是一种平台技术，采用公认为安全的组分开发，克服了与当前氧化铁纳米颗粒T2成像剂相关的时间和空间成像挑战，并且在血管疾病中具有用于检测不稳定破裂斑块或治疗动脉粥样硬化血管生成的治疗诊断潜力。
Nanomedicine approaches to atherosclerotic disease will have significant impact on the practice and outcomes of cardiovascular medicine. Iron oxide nanoparticles have been extensively used for nontargeted and targeted imaging applications based upon highly sensitive T2* imaging properties, which typically result in negative contrast effects that can only be imaged 24 or more hours after systemic administration due to persistent blood pool interference. Although recent advances involving MR pulse sequences have converted these dark contrast voxels into bright ones, the marked delays in imaging from persistent magnetic background interference and prominent dipole blooming effects of the magnetic susceptibility remain barriers to overcome. We report a T1-weighted (T1w) theranostic colloidal iron oxide nanoparticle platform, CION, which is achieved by entrapping oleate-coated magnetite particles within a cross-linked phospholipid nanoemulsion. Contrary to expectations, this formulation decreased T2 effects thus allowing positive T1w contrast detection down to low nanomolar concentrations. CION, a vascular constrained nanoplatform administered in vivo permitted T1w molecular imaging 1 hour after treatment without blood pool interference, although some T2 shortening effects on blood, induced by the superparamagnetic particles persisted. Moreover, CION was shown to encapsulate antiangiogenic drugs, like fumagillin, and retained them under prolonged dissolution, suggesting significant theranostic functionality. Overall, CION is a platform technology, developed with generally recognized as safe components, that overcomes the temporal and spatial imaging challenges associated with current iron oxide nanoparticle T2 imaging agents, and which has theranostic potential in vascular diseases for detecting unstable ruptured plaque or treating atherosclerotic angiogenesis.
登录
查看更多内容
影响因子：
5
作者：
FRANK, H;WEISSLEDER, R;BRADY, TJ
通讯作者：
BRADY, TJ
影响因子：
37.8
作者：
Flacke, S;Fischer, S;Lanza, GM
通讯作者：
Lanza, GM
影响因子：
2.7
作者：
BIBETTE, J
通讯作者：
BIBETTE, J
影响因子：
3.3
作者：
Marckmann, Peter
通讯作者：
Marckmann, Peter
影响因子：
3.3
作者：
Mani, V;Briley-Saebo, KC;Fayad, ZA
通讯作者：
Fayad, ZA